OpenNashPodcasts

Person

Vas Narasimhan

This page collects what Vas Narasimhan, the chief executive of Novartis, said on three podcasts: The a16z Show, STAT's The Readout Loud and Fortune's Leadership Next. The conversations cover drug development, company deals, gene therapy, drug pricing and leading through the COVID-19 pandemic.

On The a16z Show, Narasimhan said that on average only one in 20 medicines brought into humans works. He told STAT's The Readout Loud that Novartis did roughly $100 billion of transactions over about five years. On Leadership Next, he said he had guessed 18 months to two years for a COVID-19 vaccine. Each fact below has his exact words and a link to the moment.

3 episodes · 46 quoted claims

Vas Narasimhan says Novartis did about $50 billion of deals around 2018 to reshape the company.

“we transacted in 2018 around $50 billion of deals to really change the shape of the company”

The a16z Show · 0:02:18

Novartis decided to spin off its Alcon business, exiting medical devices and contact lenses.

“A decision to spin our Alcon business, which is to get out of medical devices and contact lenses.”

The a16z Show · 0:02:45

Vas Narasimhan says that on average only one in 20 medicines brought into humans works.

“Still, when we bring a medicine into human beings, on average, only one out of 20 works.”

The a16z Show · 0:04:49

Narasimhan says Novartis's clinical success rate is about 8-10%, versus about 5% across the industry.

“We average in that same metric about 8 % to 10%. But if you look industry-wide, it is about 5%.”

The a16z Show · 0:05:09

Narasimhan says Novartis is the world's largest producer of penicillins.

“we're the largest producer, for example, of penicillins in the world.”

The a16z Show · 0:12:03

Narasimhan says Novartis reaches about a billion patients a year, much of it through its Sandoz generics unit.

“I mean, right now Novartis reaches about a billion patients a year through our work. And a lot of that is through our Sandoz generics unit.”

The a16z Show · 0:12:31

Novartis launched, with Pear Therapeutics, a digital app with an FDA label for opioid addiction and other psychiatric illnesses.

“this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses”

The a16z Show · 0:13:45

Novartis acquired the gene therapy company AveXis to accelerate its own gene therapy work.

“we acquired a company called Avexis, really, I think, the front leading edge gene therapy company.”

The a16z Show · 0:18:23

Narasimhan says Novartis made $15 billion of acquisitions in advanced therapy platforms in the prior year.

“We've done $15 billion of acquisitions just last year in the space, not including all of our internal work in each of these areas.”

The a16z Show · 0:17:06

Novartis is developing an RNA interference therapy targeting LP(a), a heart disease risk factor.

“RNA interference to impact a factor that's really a big part of heart disease. It's called LP little a.”

The a16z Show · 0:25:20

Narasimhan says that from the late 1980s the industry learned to make large-molecule biologics such as antibodies and proteins.

“Around the late 1980s, we realized you could actually make large molecules, large proteins, and make them be therapeutic.”

The a16z Show · 0:27:10

Cell therapy edits cells outside the body (ex vivo), while gene therapy edits DNA inside the body (in vivo).

“So we make that distinction of cell therapy and gene therapy. So cell therapy is ex vivo, gene therapy is in vivo.”

The a16z Show · 0:28:07

Novartis built an operational command center called Sense over two and a half years to monitor its clinical trials.

“We've built an operational command center. It takes us, as I said, two and a half years to build it. We call it Sense.”

The a16z Show · 0:38:09

Narasimhan says Novartis runs about 400 to 500 clinical trials a year, giving it data to train AI forecasting models.

“And we run about 400 to 500 clinical trials a year. So we have a lot of data that we could train the algorithms.”

The a16z Show · 0:38:31

Novartis is digitizing its pathology images so AI can scan them, in a project called PathAI.

“we're in the process of digitizing all of our pathology images and having AI just be able to scan all of the pathology images at Novartis.”

The a16z Show · 0:37:03

Narasimhan cites estimates that deploying technology at scale could cut about 20% of clinical trial costs.

“there are estimates now from various sources that believe you could take out 20 % of clinical trials costs if you were actually to really deploy technology at scale.”

The a16z Show · 0:07:08

Narasimhan says he has explored sensors in clinical trials for at least six years, but they have struggled to meet clinical-grade validation.

“we've been really trying to explore the use of sensors in clinical trials now for, in my own experience, at least six years.”

The a16z Show · 0:43:08

Novartis's three main research hubs are Cambridge, Basel and Shanghai.

“Our three main hubs are in Cambridge, in Basel, Switzerland, and in Shanghai, in China.”

The a16z Show · 0:47:38

Narasimhan says Novartis has 17,000 R&D staff and spends more than $9 billion a year on R&D.

“we have 17 ,000 R &D people and spend $9 billion plus a year in R &D.”

The a16z Show · 0:50:15

Novartis describes its new company culture as 'inspired, curious, and unbossed'.

“And so we call our new culture inspired, curious, and unbossed.”

The a16z Show · 0:34:35

Vas Narasimhan said vaccines have typically taken 10 to 12 years to develop for any single targeted pathogen.

“vaccines typically have taken us 10 to 12 years to develop for any one of the pathogens that we're targeting.”

Leadership Next (Fortune) · 0:05:27

Vas Narasimhan said he had put out an estimate of 18 months to two years for a COVID-19 vaccine, which he described as a guess.

“I put out a number of 18 months”

Leadership Next (Fortune) · 0:07:30

Narasimhan said that during the 2009 H1N1 pandemic the main challenge was scaling up manufacturing of the vaccine.

“scaling up for the H1N1 pandemic in 2009, the real challenge was the manufacturing scale up”

Leadership Next (Fortune) · 0:08:49

Novartis was running three pivotal studies of its cancer drug Jakavi, a JAK inhibitor, as a possible COVID-19 treatment.

“we have trials right now ongoing, three pivotal studies ongoing with a drug called JAKAV, which is a JAK inhibitor”

Leadership Next (Fortune) · 0:11:13

Narasimhan said Novartis was among a group of companies that pioneered biotechnology, including antibody drugs and protein drugs.

“Later on, a group of companies, including us, pioneered biotechnology, the use of antibodies, larger drugs, proteins”

Leadership Next (Fortune) · 0:12:22

Novartis has developed cell and gene therapies aimed at B cell cancers and at spinal muscular atrophy.

“In our own work at Novartis, we've targeted B cell cancers as well as rare genetic diseases like spinal muscular atrophy.”

Leadership Next (Fortune) · 0:13:29

Narasimhan cited reports that over 60 to 70% of physicians saw a dramatic drop in patient visits during the pandemic.

“you have over 60, 70 % of physicians reporting that they are seeing a dramatic reduction in patient visits.”

Leadership Next (Fortune) · 0:16:23

Narasimhan cited a 30% drop in ER arrivals for heart attack and stroke and 80 to 90% lower cancer screening, the latter from one study.

“You see 30 % reductions in heart attack and stroke coming into the ER, epileptic seizures, reductions in cancer screening of 80 to 90%, I read in one study.”

Leadership Next (Fortune) · 0:16:23

Narasimhan said roughly 20% to 40% of physician visits were being covered by telemedicine during the pandemic.

“I understand it's on the order of 20 % to 40 % of visits are now getting covered somehow by telemedicine.”

Leadership Next (Fortune) · 0:16:52

Narasimhan said there have probably been 12 or 13 pandemics during Novartis's roughly 250-year history.

“there's probably been about 12 pandemics, 13 pandemics in the history that Novartis has been around in the last 250 years.”

Leadership Next (Fortune) · 0:18:03

The WHO's International Health Regulations set out how member countries should communicate outbreaks and originally targeted cholera, yellow fever and bubonic plague.

“international health regulations, which is a WHO regulation that really stipulates how member countries should communicate outbreaks. It primarily targeted cholera, yellow fever and bubonic plague.”

Leadership Next (Fortune) · 0:19:10

Novartis is taking its top 300 leaders, and eventually wants to take 10,000, through a program on leading in complexity.

“what we're taking our top 300 and eventually want to take our top 10 ,000 leaders on a journey on is how to lead in complexity.”

Leadership Next (Fortune) · 0:21:42

Narasimhan said the Novartis leadership program began about 18 months earlier and is based on adult development theory.

“this was actually a program we started, interestingly, 18 months ago, based on something called adult development theory”

Leadership Next (Fortune) · 0:22:11

Narasimhan said Novartis has over 100,000 employees, operates in over 150 countries and produces 72 billion doses of medicine a year.

“Over 100 ,000 people, we operate in over 150 countries. We produce 72 billion doses of medicine every year.”

Leadership Next (Fortune) · 0:24:06

Narasimhan co-chaired a CEO initiative with Bill Gates involving 17 global biopharmaceutical companies focused on equitable access to COVID-19 vaccines and drugs.

“co-lead the Gates CEO initiative with Bill Gates as the current co-chair with him. And in that discussion, so much of the focus amongst the 17 global biopharmaceutical companies”

Leadership Next (Fortune) · 0:26:29

Novartis said it was supporting about 65 projects and had just announced one with the International Rescue Committee for refugees in East Africa.

“we're supporting some 65 projects. And we just recently announced a project with the International Rescue Committee for Refugees in East Africa.”

Leadership Next (Fortune) · 0:27:10

Vas Narasimhan argues that the Inflation Reduction Act's nine years before price controls for small-molecule drugs is too short to allow indication expansions, rare disease work and oncology and cardiovascular development.

“we believe that the nine years of protection before price controls take hold in the small molecule space is simply too short to really allow us to do the indication expansions”

The Readout Loud (STAT) · 0:17:23

Narasimhan said that in many drug classes, rebates can be as much as 70% of a drug's list price.

“as you know, in many drug classes, that rebate can be as much as 70 % of the list price of the drug.”

The Readout Loud (STAT) · 0:18:22

Narasimhan said small-molecule drugs, which face price setting after nine years under the Inflation Reduction Act, make up about 60% of the drugs the industry generates.

“that will have a big impact on what is really about 60% of the drugs this industry generates and many of those drugs targeting the elderly population.”

The Readout Loud (STAT) · 0:20:04